Vancouver researchers have discovered the cellular pathway that causes lung-damaging inflammation in cystic fibrosis (CF), and that reducing the pathway's activity also decreases inflammation. The finding offers a potential new drug target for treating CF lung disease, which is a major cause of illness and death for people with CF.
"Developing new drugs that target lung inflammation would be a big step forward," says Dr. Stuart Turvey, who led the research. Dr. Turvey is the director of clinical research and senior clinician scientist at the Child & Family Research Institute and a pediatric immunologist at BC Children's Hospital. He is an associate professor in the Department of Pediatrics at the University of British Columbia.
The research was published online last week in the Journal of Immunology.
For the study, researchers compared the immune response of normal lung cells with that of CF lung cells after exposing both types of cells to bacteria in the lab. In healthy cells, exposure to bacteria triggers the cell to secrete special molecules that attract immune cells to fight the infection.
In CF lung cells, the researchers discovered that a series of molecular events called the unfolded protein response is more highly activated. It causes the CF lung cells to secrete more molecules that attract an excessive amount of immune cells, which leads to increased inflammation.
They also found that treating the CF cells with a special chemical normalized the unfolded protein response and stabilized the cells' immune response.
CF is the most common genetic disease affecting young Canadians. One in every 3600 children born in Canada has CF. There is no cure. A build-up of mucus in the lungs causes people with CF to be susceptible to bacterial lung infections, which trigger inflammation and swelling. Over time, the recurring cycle of infections and inflammation damages the lungs and can lead to the need for lung transplantation. The only treatments for lung inflammation are steroids and anti-inflammatory medications, which can have significant side effects.
The researchers are planning further study to validate these findings in a larger number of lung cell samples from people with CF.
Child & Family Research Institute: http://www.cfri.ca/
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
A recent article argued that sexuality is down to choice, not genetics. But the scientific evidence says otherwise, and points to a strong biological origin
When I hear the word “sabertooth”, my mind immediately jumps to the great sabercats who sliced through throats …
The Portland Press Herald reports that "Captain Eli," a rare orange lobster, will be kept at the Fisherman's Catch Café in Raymond, Maine, before Bill Coppersmith releases it back into the ocean.
A very rare genetic mutation causes some people to develop Alzheimer's in their 30s. It also makes these people the ideal candidates for tests of potential Alzheimer's drugs.
Adding pigment may shield eggs from UV radiation
Atlantic bottlenose and spotted dolphins are cooperating in unique mixed-species groups that are mostly platonic, but sometimes cross-species sex is involved
Manuscript found by student may date to Islam’s earliest era.
Conventional wisdom held that pythons and anacondas suffocate their prey. Instead, the predators cut off their victims' blood supply, a new study says.
Solanezumab blocks memory loss in patients with mild version of the disease, making it the first medicine ever to slow pace of damage to patients’ brains
New research provides a potential pathway to a drug to save people from the progressive damage of severe or repeated concussions.